Sai Parenteral’s IPO Description – Sai Parenteral’s is a diversified pharmaceutical formulations player with integrated capabilities across research, development, and manufacturing, operating through two core verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. Its product portfolio spans multiple high-demand therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, dermatology, and vitamins, minerals and supplements. The company offers a wide range of dosage forms such as injectables, tablets, capsules, liquid orals, ointments and dry syrups, with particular strength in sterile injectable manufacturing for critical care and penicillin-based therapies.
The company owns and operates five manufacturing facilities in India with aggregate installed capacity of 1,160 million units per annum, supported by multiple regulatory accreditations, including WHO-GMP, PIC/S and TGA-Australia.
The company has a presence in markets such as Australia, New Zealand, Southeast Asia, the Middle East and Africa. As of 31 December 2025, the company have 298 full-time employees.
Promoters of Sai Parenteral’s IPO – Anil Kumar Karusala, Vijitha Gorrepati, Karusala Aruna
Table of Contents
Sai Parenteral’s IPO Details
| Sai Parenteral’s IPO Dates | 24 – 27 March 2026 |
| Sai Parenteral’s IPO Issue Price | Coming soon |
| Fresh Issue | INR 285 crore |
| Offer For Sale | 31,57,880 shares |
| Total IPO Size | Coming soon |
| Minimum Bid (Lot Size) | Coming soon |
| Pre-issue Shares | 3,69,08,823 shares |
| Face Value | INR 5 per share |
| Listing On | NSE, BSE |
Sai Parenteral’s IPO Allocation in Different Categories
Sai Parenteral’s IPO Financial Performance
| FY 2023 | FY 2024 | FY 2025 | H1 FY 2026 | |
| Revenue | 96.80 | 153.76 | 163.11 | 86.92 |
| Expenses | 89.78 | 142.63 | 143.84 | 78.27 |
| Net Income | 4.38 | 8.42 | 14.45 | 7.76 |
| Margin (%) | 4.52 | 5.48 | 8.86 | 8.93 |
Sai Parenteral’s Offer News
- Sai Parenteral’s IPO RHP
- Sai Parenteral’s IPO DRHP
- Sai Parenteral’s IPO Anchor Investors
- ASBA IPO Forms
- IPO Process in India
- Live IPO Subscription Status
- IPO Allotment Status
Sai Parenteral’s IPO Valuations & Margins
| FY 2023 | FY 2024 | FY 2025 (Pre-Issue) | FY 2026 (Post-Issue) | |
| EPS | 6.16 | 10.54 | 5.43 | – |
| PE Ratio | – | – | – | – |
| FY 2023 | FY 2024 | FY 2025 | |
| RONW (%) | 13.90 | 11.01 | 15.09 |
| Price/Book Ratio | – | ||
| Current Ratio | 1.07 | 1.23 | 1.23 |
| Price/Sales Ratio | – | ||
| NAV | 44.03 | 57.67 | 35.98 |
| ROCE (%) | 21.04 | 20.52 | 28.92 |
| EBITDA (%) | 18.22 | 20.62 | 24.18 |
| Debt/Equity | 2.18 | 1.55 | 0.98 |
Evaluate the quality of an IPO using these essential investing ratios to make an informed decision.
Sai Parenteral’s IPO Anchor Investors
Sai Parenteral’s raises () from anchor investors. Sai Parenteral’s IPO Anchor bid date is 23 March 2026.
| Bid Date | 23 March 2026 |
| Shares Offered | Coming soon |
| Anchor Portion (INR Cr.) | Coming soon |
| Anchor lock-in period end date for 50% shares (30 Days) | 27 April 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | 29 June 2026 |
Sai Parenteral’s IPO GMP Today (Daily Trend)
| Date | Consolidated IPO GMP | Subject to Sauda |
| 17 March 2026 | 0 | 0 |
Sai Parenteral’s Offer Objectives
The company proposes to utilize net proceeds from the issue towards the following objects:
- Capacity expansion and upgradation of manufacturing facilities – INR 110.80 crore
- Establishment of a new R&D Centre – INR 18.02 crore
- Repayment/prepayment of certain outstanding borrowings – INR 14.30 crore
- Working capital requirements – INR 33.00 crore
- Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty (Australia) – INR 35.64 crore
- General Corporate Purposes
Sai Parenteral’s Public offer – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Sai Parenteral’s | – | 5.43 | 15.09 | 35.98 | 163.11 |
| Sai Life Sciences | 107.70 | 8.61 | 7.99 | 102.12 | 1,694.57 |
| Innova Captab | 32.45 | 22.41 | 13.37 | 167.66 | 1,243.68 |
| Senores Pharmaceuticals | 64.30 | 16.12 | 7.18 | 176.37 | 398.25 |
| Gland Pharma | 44.71 | 42.40 | 7.63 | 555.41 | 5,616.50 |
Sai Parenteral’s IPO Allotment Status
You can check Sai Parenteral’s IPO allotment status on the Bigshare Services website. Click on this link to get the allotment status. Often not getting IPO allotment? Learn how to improve your IPO allotment chances.
Sai Parenteral’s IPO Dates & Listing Performance
| IPO Opening Date | 24 March 2026 |
| IPO Closing Date | 27 March 2026 |
| Finalization of Basis of Allotment | 30 March 2026 |
| Initiation of refunds | 1 April 2026 |
| Transfer of shares to demat accounts | 1 April 2026 |
| Sai Parenteral’s IPO Listing Date | 2 April 2026 |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Sai Parenteral’s Offer Lead Manager
ARIHANT CAPITAL MARKETS LIMITED
1011, Solitaire Corporate Park, Guru Hargovindji Road,
Chakala, Andheri (E), Mumbai – 400 093
Tel: 022-42254800
Email: [email protected]
Website: www.arihantcapital.com
Sai Parenteral’s Offer Registrar
BIGSHARE SERVICES PRIVATE LIMITED
Office No S6-2 6th Floor, Pinnacle Business Park,
Mahakali Caves Rd, next to Ahura Centre,
Andheri East, Mumbai-400093
Tel: 022-62638200
E-mail: [email protected]
Website: www.bigshareonline.com
Sai Parenteral’s Offer Contact Details
SAI PARENTERAL’S LIMITED
Plot No 39, 5th floor, Lavanya Arcade,
Jayabheri Enclave, Gachibowli, K.V.Rangareddy,
Seri Lingampally 500032, Telangana, India
Tel: +91 79979 91301
E-mail: [email protected]
Website: www.saiparenterals.com
IPO Resources
- IPO Investing Rules: 10 Commandments for Better IPO Returns
- Pre-IPO Shares: All you want to know
- Difference Between Primary Market and Secondary Market
- 5 Tips for Selecting an IPO to Invest In
- IPO Process in India: All you need to know
- 7 common IPO mistakes and how to avoid them
- Confidential IPO Filings in India: Everything You Need to Know
Sai Parenteral’s Public Offer FAQs
How many shares in Sai Parenteral’s IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Sai Parenteral’s Public Offer?
The best way to apply for Sai Parenteral’s public offer is through Internet banking ASBA (know all about ASBA here) before the last day cut-off time. You can also apply online through your stockbroker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Sai Parenteral’s IPO GMP today?
Sai Parenteral’s IPO GMP today is INR 0 per share.
What is Sai Parenteral's IPO Subject to Sauda rate today?
Sai Parenteral’s IPO Subject to Sauda rate today is INR 0 per application.
Krishna comes from a family of investors and financial analysts, She learnt wading through regulatory filings pretty early in her career. She has several years of experience in financial and industry analysis under her belt. At IPO Central, Krishna plays twin roles of Contributor and Head of research desk.